All right, so welcome back to the Internet Book of Critical Care podcast. I'm here with Adam Thomas,

and we're at update number five on COVID. The eternity continues. I don't even know what week

we're on, Josh, but it's been going since December. I don't know. I've lost all track of time.

Time doesn't exist anymore. So today, let's cover more experience coming out of New York City. When anyone can publish a cohort of 12,000 patients, that is Beast Mode.

So it's very impressive. We'll also delve into, again, the pathophysiology of AARDS, pseudo-ARDS,

in this new potential paradigm. We'll talk about emerging pathology when it comes to lung

injury. We'll balance the post that Josh had this week around research infrastructure and the

spectrum that is out there. And then we cannot not pay homage to the ongoing bunfight around

Remdesivir. So Josh, let's get straight into our sponsor for today's

podcast. Yeah, so this podcast is sponsored by Big Urea. And I think it's really important to recognize

in these times how important urea is. There's actually an unrecognized body of evidence that

urea can prevent the replication of COVID. So right now, I just want to say up front, we're going to recommend putting all of our patients on urea.

This is a critical intervention to prevent COVID.

We're going to leave this at the podcast.

This is a cheeky joke.

I'm just going to underscore this.

So everyone's clear, urea does nothing for COVID.

That is a joke.

There's some crazy shit going on Twitter these days and people

are all fired up. Everyone just needs to put their laptop or phone away for a minute and go

walk on the porch or something. But Josh, let's just say this. You and I do not have financial

conflicts of interest. We never do. So the point with maybe this shout out this week, we'll just say bygones be bygones and let's forget about it.

...